Join us at Society for Immunotherapy of Cancer (SITC)'s #SITC2024 for updates from our HPK1 inhibitor program. Principal Investigator David Sommerhalder of NEXT Oncology San Antonio will present clinical data in renal cell carcinoma, while our Senior Director of Translational Medicine Scott Daigle will share immune activation insights from the study on November 8-9. Learn more in our official data release here: https://lnkd.in/e8D-6VsG #SITC
Nimbus Therapeutics
Biotechnology Research
Boston, Massachusetts 15,900 followers
We develop breakthrough medicines for patients through precision small molecule design.
About us
Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. The company advances promising research based on a unique strategy that combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus' pipeline includes a clinical-stage HPK1 inhibitor for the treatment of cancer (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, including a WRN program for MSI-H cancers, autoimmune conditions, and metabolic diseases.
- Website
-
http://www.nimbustx.com/
External link for Nimbus Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2009
- Specialties
- computational chemistry, biochemistry, small molecule therapeutics, oncology, immunology, metabolism, and drug development
Locations
-
Primary
Get directions
22 Boston Wharf Rd
9th Fl
Boston, Massachusetts 02210, US
Employees at Nimbus Therapeutics
Updates
-
“I am exceptionally excited about what Nimbus already is and is becoming even more so – a powerhouse R&D organization.” - Jeb Keiper, CEO As we wind down our celebration of our 15-year anniversary, we’re excited for what the future of Nimbus holds. Hear from our CEO Jeb Keiper, CBO Abbas Kazimi and CPO Erin Cowhig about our mission to develop breakthrough medicines for patients, our drive for innovation, and the incredible team that will shape the next 15 years and beyond. Nimbustx.com #Nimbus15
-
Proud to see fellow #Nimbi David Ciccone, Sr Director, Biology, representing Nimbus at yesterday's Inflammation Research Association symposium! His presentation on HPGD inhibitor pharmacology showcased how our computational and structural biology expertise drives innovative drug discovery. Amazing to see the breadth of inflammation research advancing across the field! #DrugDiscovery #Inflammation
Agenda is set. Registration is filling up fast and space is limited so secure a spot now! The organizers have assembled a diverse lineup of speakers representing pharma, life science venture capital, biotech and academia. Click HERE for the agenda https://lnkd.in/eCEDVjUC Click HERE to register https://lnkd.in/eA4DvTsH
-
-
On Friday, we attended The Admin Awards in Boston to celebrate our Director of Executive Operations Nicole Tritta Gallagher, who was among the distinguished nominees for the Strategic Partnership Award. This award recognizes excellence in executive assistance, business partnerships, and delivering strategic value to an organization and its executives. Nicole’s work is integral to our success and the #Nimbi team was proud to celebrate her achievements and well-deserved nomination at this event!
-
-
Next week, #Nimbi Gene Yau and Robert Svensson are attending #BIOEurope in Stockholm, Sweden, Europe’s largest #lifesciences partner networking event produced by EBD Group. Looking forward to meaningful discussions and discovering new collaboration opportunities. See you in Stockholm!
-
-
Halloween is an annual favorite for our #Nimbi, and this year was no exception! The team went all out with creative spooky costumes and showed off their pumpkin carving skills. Happy Halloween!
-
-
We talk a lot about our culture because it’s the driving force behind our success. We’ve made deliberate investments in our people, fostering trust and collaboration while keeping our mission in focus. Our Chief People Officer Erin Cowhig joined our CEO Jeb Keiper and CBO Abbas Kazimi to discuss why culture is our “special sauce” and has kept us moving forward on our 15-year journey. Nimbustx.com #Nimbus15
-
On Friday, we had the pleasure of attending Bottom Line’s inaugural Go Far, Give Back Soirée in support of local students striving for access to higher education opportunities. Bottom Line works to help give aspiring young professionals from under-resourced communities the tools to succeed through higher education and beyond, and Nimbus is proud to sponsor events like last week’s Soirée that further their support of students in the Boston area. Thank you to everyone who came out! Learn more about Bottom Line’s work on their website: https://lnkd.in/dijpMiM
-
-
Daniel Price, Nimbus VP, Computational Chemistry and Structural Biology, joins distinguished industry leaders Polaris - Benchmarks for methods that matter's Small Molecule Steering Committee. The initiative aims to bridge the gap between ML innovation and real-world drug discovery impact through standardized benchmarking. Read their foundational publication in Nature Magazine, and the full announcement below:
Excited to introduce the first steering committee (SC) from Polaris! This group of industry experts is focused on small-molecule, predictive modeling tasks and is collaborating to develop guidelines for benchmarking best practices. At Polaris, our mission is to bring innovators and practitioners closer together to develop methods that matter. The first SC publication in Nature Machine Intelligence outlines the common challenges in benchmarking and serves as a call-to-action for the community emphasizing the importance of cross-industry collaboration. Next, we’ll be releasing a pre-print on method comparison, providing guidance on comparison protocols and domain-appropriate performance metrics to ensure reproducibility in real-world settings. Read the correspondence letter: https://rdcu.be/dVZHz Read the announcement: https://lnkd.in/eMChDMsh See the Guidelines page: https://lnkd.in/eNBfTTXt Jeremy A. Pat Walters Alan Cheng Djork-Arné Clevert Daniel Price Cheng Fang Cas Wognum Matteo Aldeghi Ola Engkvist Raquel Rodríguez-Pérez
-
-
Join us this Friday, October 25 at the 36th EORTC-NCI-AACR Symposium in Barcelona, Spain where we'll present our first preclinical data on NTX-452, our novel non-covalent WRN inhibitor clinical candidate. Our Senior Director of Biology Robert Svensson will share how NTX-452 demonstrated significant anti-tumor activity across multiple MSI-H preclinical models. Read the data release here: https://bit.ly/4ffZTKU #ENASymp24 EORTC - European Organisation for Research and Treatment of Cancer, National Cancer Institute (NCI), American Association for Cancer Research
-